Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q4 FY19 results · Jan–Mar 2019
Solara Active Pharma Sciences reported revenue from operations of ₹385.31 crore and net profit of ₹26.20 crore for Q4 FY19 (Jan–Mar 2019), on a consolidated basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 385.31 | — | — | 356.23 | +8.2% |
| Other income | 6.63 | — | — | 3.88 | +70.9% |
| Total income | 391.94 | — | — | 360.11 | +8.8% |
| Profit before tax | 26.16 | — | — | 22.10 | +18.4% |
| Net profit for the period | 26.20 | — | — | 22.10 | +18.6% |
| Attributable to shareholders of the company | 26.32 | — | — | 22.09 | +19.1% |
| EPS, basic (₹) | 10.17 | — | — | 8.96 | +13.5% |
| Net margin (%) | 6.8 | — | 6.2 |
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 380.10 | — | — | 347.94 | +9.2% |
| Other income | 3.63 | — | — | 2.52 | +44.0% |
| Total income | 383.73 | — | — | 350.46 | +9.5% |
| Profit before tax | 28.44 | — | — | 24.39 | +16.6% |
| Net profit for the period | 27.06 | — | — | 24.39 | +10.9% |
| EPS, basic (₹) | 10.48 | — | — | 9.89 | +6.0% |
| Net margin (%) | 7.1 | — | 7.0 |
Consolidated
- Filed with BSE
- 18 May 2019, 15:19 IST
- Board meeting
- 16 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 May 2019, 15:19 IST
- Board meeting
- 16 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE